A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

NCT02554812

Last updated date
Study Location
Koman Family Outpatient Pavilion
La Jolla, California, 92037, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological or cytological diagnosis of advanced/metastatic solid tumor. Measurable disease by RECIST 1.1 with at least 1 measurable lesion that has not been previously irradiated. Availability of tumor specimen taken within 1 year prior to study entry, with no intervening systemic anti-cancer therapy. No prior PD-1/PDL-1 therapy allowed. Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC. 1st line NSCLC must demonstrate to express PD-L1. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination B: Phase 1b, patients with advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, or SCCHN. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination C: Ovarian cancer, SCCHN, NSCLC, gastric cancer, platinum resistant ovarian cancer. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. TGCT/PVNS that is either inoperable or requires extensive resection. Prior treatment with agents targeting CSF-1/CSF-1R not allowed. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination D: NSCLC, melanoma, SCCHN, bladder cancer. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Combination F: Recurrent or metastatic SCCHN. One to three prior lines of systemic therapy for advanced stage or metastatic disease. Patients must have received anti PD-1/PD-L1 containing therapy (requires at least two doses of PD-1/PD-L1 agent).Disease progression no earlier than 6 weeks from initiation of the latest anticancer therapy. Evidence of radiologic progression is required. • Patient must be a candidate for intralesional administration with at least one tumor lesion which can be injected safely.

- ECOG performance status 0 or 1

- Estimated life expectancy of at least 3 months

- Adequate bone marrow, renal, and liver function

- Resolved acute effects of prior therapy

- Negative serum pregnancy test at screening

- Male and female patients able to have children must agree to use at least 1 highly effective method of contraception throughout the study and for at least 90 days after last dose

- Signed and dated informed consent

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Monoclonal antibody based anti-cancer therapy within 28 days prior to study entry or
small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14
days prior to study entry. Combination F:PD-1/PD-L1 agent within 14 days prior study
entry.


- Current or prior use of immunosuppressive medication within 7 days prior to study
entry


- Active autoimmune disease requiring systemic steroids or immunosuppressive agents
within 7 days prior to study entry


- Known prior or suspected hypersensitivity to investigational products


- Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry


- Patients with known symptomatic brain metastases requiring steroids


- Previous high-dose chemotherapy requiring stem cell rescue


- Prior allogeneic stem cell transplant or organ graft


- Any of the following within 6 months prior to study entry: myocardial infarction,
uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive
heart failure, cerebrovascular accident, or transient ischemic attack


- Symptomatic pulmonary embolism within 6 months prior to study entry


- Known HIV or AIDS-related illness


- Active infection requiring systemic therapy


- Positive HBV or HCV test indicating acute or chronic infection


- Administration of a live vaccine within 4 weeks prior to study entry


- Diagnosis of other malignancy within 5 years, except for adequately treated basal cell
or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or
low-grade (Gleason ≤6) prostate cancer


- Participation in other studies involving investigational drug(s) within 4 weeks prior
to study entry and/or during study participation


- Persisting toxicity related to prior therapy >Grade 1


- Other severe acute or chronic medical condition


- Combo C :Existing periorbital edema.


- Combo C : Hypocalcemia, clinically significant bone disease or recent bone fracture
(within 12 weeks prior study entry)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Advanced CancerThe Effect of Donepezil on Sedation and Other Symptoms
NCT00352664
  1. Houston, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced CancerClinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
NCT01347866
  1. Los Angeles, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Santa Monica, California
  6. Santa Monica, California
  7. Aurora, Colorado
  8. Aurora, Colorado
  9. Aurora, Colorado
  10. Aurora, Colorado
  11. Charleston, South Carolina
  12. Charleston, South Carolina
  13. Charleston, South Carolina
  14. Mount Pleasant, South Carolina
  15. North Charleston, South Carolina
  16. Toronto, Ontario
  17. Milano,
  18. Barcelona,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced CancerA Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
NCT02554812
  1. La Jolla, California
  2. La Jolla, California
  3. Clinton, North Carolina
  4. Goldsboro, North Carolina
  5. Jacksonville, North Carolina
  6. Encinitas, California
  7. La Jolla, California
  8. La Jolla, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. San Diego, California
  14. Vista, California
  15. Washington, District of Columbia
  16. Aventura, Florida
  17. Miami Beach, Florida
  18. Sarasota, Florida
  19. Tampa, Florida
  20. Iowa City, Iowa
  21. Ann Arbor, Michigan
  22. Ann Arbor, Michigan
  23. Detroit, Michigan
  24. Detroit, Michigan
  25. Farmington Hills, Michigan
  26. Northville, Michigan
  27. New York, New York
  28. New York, New York
  29. New York, New York
  30. New York, New York
  31. New York, New York
  32. New York, New York
  33. New York, New York
  34. New York, New York
  35. Clinton, North Carolina
  36. Goldsboro, North Carolina
  37. Jacksonville, North Carolina
  38. Philadelphia, Pennsylvania
  39. Providence, Rhode Island
  40. Providence, Rhode Island
  41. Sioux Falls, South Dakota
  42. Sioux Falls, South Dakota
  43. Sioux Falls, South Dakota
  44. Sioux Falls, South Dakota
  45. Nashville, Tennessee
  46. Nashville, Tennessee
  47. Nashville, Tennessee
  48. Nashville, Tennessee
  49. Dallas, Texas
  50. Dallas, Texas
  51. Houston, Texas
  52. Seattle, Washington
  53. Seattle, Washington
  54. Camperdown, New South Wales
  55. Macquarie University, New South Wales
  56. Macquarie University, New South Wales
  57. North Sydney, New South Wales
  58. North Sydney, New South Wales
  59. Old Toongabie, New South Wales
  60. Brighton, Victoria
  61. Brighton, Victoria
  62. Heidelberg, Victoria
  63. Malvern, Victoria
  64. Malvern, Victoria
  65. Malvern, Victoria
  66. Malvern, Victoria
  67. New South Wales,
  68. New South Wales,
  69. Edmonton, Alberta
  70. Vancouver, British Columbia
  71. Ottawa, Ontario
  72. Toronto, Ontario
  73. Montreal, Quebec
  74. Montreal, Quebec
  75. Villejuif, Cedex
  76. Villejuif,
  77. Kashiwa, Chiba
  78. Chuo-ku, Tokyo
  79. Warszawa, Mazowieckie
  80. Poznan, Wielkopolskie
  81. Poznan, Wielkopolskie
  82. Poznan, Wielkopolskie
  83. Poznan, Wielkopolskie
  84. Taipei,
  85. Taipei,
  86. London,
  87. London,
  88. London,
  89. London,
  90. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced CancerHepatic Impairment Study For Crizotinib In Advanced Cancer Patients
NCT01576406
  1. Los Angeles, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Aurora, Colorado
  6. Aurora, Colorado
  7. Aurora, Colorado
  8. Aurora, Colorado
  9. Atlanta, Georgia
  10. Atlanta, Georgia
  11. Atlanta, Georgia
  12. Atlanta, Georgia
  13. Atlanta, Georgia
  14. Columbus, Ohio
  15. Columbus, Ohio
  16. Columbus, Ohio
  17. Columbus, Ohio
  18. Columbus, Ohio
  19. San Antonio, Texas
  20. San Antonio, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Official Title  ICMJE A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES
Brief Summary This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications.
Detailed Description

This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer (TNBC), gastric cancer, platinum resistant ovarian cancer, bladder cancer, small cell lung cancer (SCLC) and progressing tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS) . In Phase 1b, this includes patients whose disease has progressed on standard of care therapy or for whom no standard therapy is available. In Phase 2, enrollment criteria regarding prior treatment(s) received varies by tumor type. Incorporation of the other immune modulators into this study is based on preclinical and clinical data supportive of single-agent tolerability and potential clinical benefit, as well as non-clinical data suggesting safety, tolerability and clinical benefit of the agent(s) in combination with avelumab. Combinations of avelumab plus other immune modulator(s) to be evaluated are as follows:

  • Combination A: avelumab plus utomilumab (4-1BB agonist mAb)
  • Combination B: avelumab plus PF-04518600 (OX40 agonist mAb)
  • Combination C: avelumab plus PD 0360324 (M-CSF mAb)
  • Combination D: avelumab plus utomilumab plus PF-04518600
  • Combination F: avelumab plus CMP-001 (TLR9 agonist) and avelumab plus CMP-001 plus utomilumab and avelumab plus CMP-001 and PF-04518600 Each combination will be studied individually in 2 study parts: 1) a Phase 1b Lead-in part to evaluate safety, and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and RP2D (if applicable), of the combination, and 2) a Phase 2 part to evaluate efficacy and further evaluate safety of the selected dose from the Phase 1b portion in pre-specified patient populations.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced Cancer
Intervention  ICMJE
  • Drug: Avelumab
    Anti-PD-L1 antibody
    Other Name: MSB0010718C
  • Drug: Utomilumab
    Anti-4-1BB antibody
    Other Name: PF-05082566
  • Drug: PF-04518600
    OX40 Agonist
  • Drug: PD 0360324
    Anti-M-CSF
  • Drug: CMP-001
    TLR9 agonist
Study Arms  ICMJE
  • Experimental: Cohort A1
    NSCLC patients treated with avelumab + utomilumab (Dose level 1)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A2
    NSCLC patients treated with avelumab + utomilumab (Dose level 2)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A3
    NSCLC patients treated with avelumab + utomilumab (Dose level 3)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A4
    Melanoma patients treated with avelumab +utomilumab
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A5
    SCCHN patients treated with avelumab + utomilumab
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A6
    TNBC patients treated with avelumab + utomilumab
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A7
    SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A8
    NSCLC first-line Stage IV treated with avelumab +PF-05082566
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Combination B Dose Escalation
    PF-04518600 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: PF-04518600
  • Experimental: Combination B Expansion Cohorts
    PF-04518600 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: PF-04518600
  • Experimental: Combination C Dose escalation cohorts
    PD 0360324 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: PD 0360324
  • Experimental: Combination C Dose expansion cohorts
    PD 0360324 + aveluamb in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: PD 0360324
  • Experimental: Combination D Dose escalation cohorts
    PF-05082566 + PF-04518600 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
    • Drug: PF-04518600
  • Experimental: Combination D Dose expansion cohorts
    PF-05082566 + PF-04518600 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
    • Drug: PF-04518600
  • Experimental: Cohort A9
    NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A10
    NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort F1
    CMP-001 +avelumab in SCCHN
    Interventions:
    • Drug: Avelumab
    • Drug: CMP-001
  • Experimental: Cohort F2
    CMP-001+avelumab+utomilumab in SCCHN
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
    • Drug: CMP-001
  • Experimental: Cohort F3
    CMP-001 +avelumab+PF-04518600 in SCCHN
    Interventions:
    • Drug: Avelumab
    • Drug: PF-04518600
    • Drug: CMP-001
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 10, 2019)
620
Original Estimated Enrollment  ICMJE
 (submitted: September 17, 2015)
147
Estimated Study Completion Date  ICMJE February 3, 2024
Estimated Primary Completion Date February 3, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histological or cytological diagnosis of advanced/metastatic solid tumor. Measurable disease by RECIST 1.1 with at least 1 measurable lesion that has not been previously irradiated. Availability of tumor specimen taken within 1 year prior to study entry, with no intervening systemic anti-cancer therapy. No prior PD-1/PDL-1 therapy allowed. Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC. 1st line NSCLC must demonstrate to express PD-L1. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination B: Phase 1b, patients with advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, or SCCHN. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination C: Ovarian cancer, SCCHN, NSCLC, gastric cancer, platinum resistant ovarian cancer. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. TGCT/PVNS that is either inoperable or requires extensive resection. Prior treatment with agents targeting CSF-1/CSF-1R not allowed. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination D: NSCLC, melanoma, SCCHN, bladder cancer. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Combination F: Recurrent or metastatic SCCHN. One to three prior lines of systemic therapy for advanced stage or metastatic disease. Patients must have received anti PD-1/PD-L1 containing therapy (requires at least two doses of PD-1/PD-L1 agent).Disease progression no earlier than 6 weeks from initiation of the latest anticancer therapy. Evidence of radiologic progression is required. ? Patient must be a candidate for intralesional administration with at least one tumor lesion which can be injected safely.
  • ECOG performance status 0 or 1
  • Estimated life expectancy of at least 3 months
  • Adequate bone marrow, renal, and liver function
  • Resolved acute effects of prior therapy
  • Negative serum pregnancy test at screening
  • Male and female patients able to have children must agree to use at least 1 highly effective method of contraception throughout the study and for at least 90 days after last dose
  • Signed and dated informed consent

Exclusion Criteria:

  • Monoclonal antibody based anti-cancer therapy within 28 days prior to study entry or small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14 days prior to study entry. Combination F:PD-1/PD-L1 agent within 14 days prior study entry.
  • Current or prior use of immunosuppressive medication within 7 days prior to study entry
  • Active autoimmune disease requiring systemic steroids or immunosuppressive agents within 7 days prior to study entry
  • Known prior or suspected hypersensitivity to investigational products
  • Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry
  • Patients with known symptomatic brain metastases requiring steroids
  • Previous high-dose chemotherapy requiring stem cell rescue
  • Prior allogeneic stem cell transplant or organ graft
  • Any of the following within 6 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack
  • Symptomatic pulmonary embolism within 6 months prior to study entry
  • Known HIV or AIDS-related illness
  • Active infection requiring systemic therapy
  • Positive HBV or HCV test indicating acute or chronic infection
  • Administration of a live vaccine within 4 weeks prior to study entry
  • Diagnosis of other malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or low-grade (Gleason ?6) prostate cancer
  • Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation
  • Persisting toxicity related to prior therapy >Grade 1
  • Other severe acute or chronic medical condition
  • Combo C :Existing periorbital edema.
  • Combo C : Hypocalcemia, clinically significant bone disease or recent bone fracture (within 12 weeks prior study entry)
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Australia,   Canada,   France,   Japan,   Poland,   Taiwan,   United Kingdom,   United States
Removed Location Countries Netherlands
 
Administrative Information
NCT Number  ICMJE NCT02554812
Other Study ID Numbers  ICMJE B9991004
2015-002552-27 ( EudraCT Number )
JAVELIN MEDLEY ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP